Safety & evidence

MOTS-c side effects:
what has been reported, and by whom

MOTS-c has no established human safety profile. Here is what the trial registry, published literature, and US regulators can tell us as of 21 November 2026.

Short answerSafety & evidence · 6 min read · Updated 21 Nov 2026

MOTS-c has no established human safety profile. As of 21 November 2026, a registered phase 2a trial had no posted results, and we found no published randomized trial that gave MOTS-c to people. FDA says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration” and that it has not identified any human exposure data.

Key takeaways

  • We found no published randomized trial that gave MOTS-c to people in our 21 November 2026 PubMed check.
  • Trial NCT07505745 plans to compare MOTS-c with placebo in an estimated 120 adults and track adverse events, but no results were posted as of 21 November 2026.
  • FDA says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”, and that it has not identified any human exposure data.
  • HHS cites a trial of a different molecule, so its account of that trial does not establish a safety profile for MOTS-c itself.

01Three sources answer different questions

If you searched “mots c side effects”, start by asking where a claimed reaction was recorded. These three sources answer different questions.

Clinical trials

What happened in each group? A trial can compare events between groups once results are available.

FDA reporting database

What was submitted to the agency? A submission is not a finding that the substance caused the event.

Published case reports

What happened to an individual patient? A case report can describe the sequence of events, but it cannot tell you how often an event occurs.

02What has been reported, and by whom?

SourceWhat the record showsWhat it cannot tell us
Hudson Biotech, ClinicalTrials.gov NCT07505745The 2026 randomized human trial plans to compare adverse events with placebo (estimated n=120). No results were posted as of 21 November 2026.Which events occurred, how often, or whether one group had more events.
Published case reportsWe found no published case report of an adverse event after MOTS-c was given to a person (PubMed, 21 November 2026).Whether an event occurred but was never documented or published.

The trial registry. In NCT07505745, one of the main questions is how often new or worsening health events occur after the study intervention begins. These are called treatment-emergent adverse events. The timing is what puts an event in that category. It does not mean the study substance caused it. This is a randomized human study design, not a set of human safety findings.

FDA’s adverse-event database. In its July 2026 briefing, FDA’s Office of Surveillance and Epidemiology said it searched the FDA Adverse Event Reporting System (FAERS) for MOTS-c through 28 February 2024, then again from 26 February 2024 through 9 March 2025. Neither search retrieved a report. That is FDA’s historical search, not a count through November 2026. FDA notes that compounders generally do not report adverse events to it, and that a report does not establish causation or show how often an event occurs.

The published literature. Measuring a peptide already in the body is different from giving it to participants. In a 2021 exercise study, Reynolds and colleagues measured naturally occurring MOTS-c in muscle and blood in 10 young men who cycled (T2, human measurements). The researchers did not give the peptide to those participants, so that part of the study tells us nothing about reactions to administered MOTS-c.

03Who is excluded from the registered trial?

The sponsor’s entry for NCT07505745 limits enrollment to adults aged 18–65 who meet its screening criteria. It does not accept healthy volunteers. Examples of the listed exclusions include:

  • Pregnancy, breastfeeding, or plans for pregnancy during the study.
  • Diabetes or recent use of glucose-lowering medication.
  • Recent clinically significant cardiovascular disease or uncontrolled high blood pressure.
  • Reduced kidney function below the trial’s cutoff, clinically significant liver disease, or liver enzyme levels above the trial’s limits.
  • Known hypersensitivity to peptide therapeutics or to an ingredient in the study formulation.

These are enrollment rules, not findings of harm. Even once results are available, the trial will not directly answer how people it excluded would respond.

04What do FDA and HHS say?

FDA’s compounding safety page. FDA says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”. Immunogenicity means the ability to trigger an immune response. FDA adds that such products “may have complexities with regard to peptide-related impurities and API characterization”. The entry remains under substances whose nominations were withdrawn. That is not a finding that the safety concern went away.

FDA’s July 2026 briefing. FDA staff did not identify clinical studies or human exposure data that would let them assess the safety of MOTS-c or MOTS-c acetate. Staff also did not identify nonclinical toxicity studies to inform that assessment. They flagged peptide clumping and impurities as possible contributors to an immune response, not as reactions observed in patients.

HHS’s October 2026 draft. The US Department of Health and Human Services names MOTS-c in its draft interim compounding enforcement policy. Appendix B says a randomized placebo-controlled trial of an unnamed analogue “reported no serious adverse events”. An analogue is a different molecule. That finding does not fill the human safety gap FDA identified for MOTS-c itself. The Federal Register notice of 30 October 2026 says the draft “is not binding on HHS or the public”.

05What we don’t know

We do not know whether MOTS-c causes reactions in people, which ones, how often, or what might emerge over longer follow-up. A lab report answers a separate question: what was tested in the sample from a particular batch.

1
Match the lot

Check that the batch identifier on the certificate of analysis (COA) matches the vial label.

2
Check identity separately

Look for a named test and result for what the material is. A purity result alone does not establish identity.

3
See what was not tested

A purity result does not tell you whether sterility or endotoxins were tested. Look for separate entries.

For examples of what each line can and cannot show, see how to read a COA. A batch report does not establish human safety.

If you think you’ve had a reaction to any product, seek medical care first. The reaction reporting guide explains where to submit a report.

This is a plain-English summary of research and public documents, dated 21 November 2026. It is not medical or legal advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document on MOTS-c-related bulk drug substances. Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026, especially pp. 22, 28–30. www.fda.gov/media/193347/download
  2. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Compounding safety page, MOTs-C entry under substances nominated but withdrawn. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  3. U.S. Food and Drug Administration. FDA Adverse Event Monitoring System Public Dashboard. FDA guide to the limitations of spontaneous adverse-event reports. www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/f…
  4. Hudson Biotech. [Phase 2a randomized MOTS-c study record, NCT07505745]. ClinicalTrials.gov, first posted 1 April 2026. Record read through the ClinicalTrials.gov API, 21 November 2026: recruiting, no results posted. clinicaltrials.gov/study/NCT07505745
  5. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Draft interim policy, Appendices A and B, pp. 4, 9–10. hhs.gov returned 403 on 21 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest readable capture. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  6. U.S. Department of Health and Human Services. Notice of availability of draft enforcement discretion policy. Federal Register, 30 October 2026; 91 FR 68526–68527, FR Doc. 2026-22192. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  7. Reynolds JC et al. [MOTS-c measurements during exercise and experiments in mice]. Nature Communications, 2021;12:470. Fig. 1 for human measurements. www.nature.com/articles/s41467-020-20790-0
  8. U.S. Food and Drug Administration. Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. Guidance for industry, 2016; section 11.4, Certificates of Analysis. www.fda.gov/media/71518/download

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is there human safety data for MOTS-c?

No human safety profile has been established. We found no published randomized trial that gave MOTS-c to people as of 21 November 2026, and FDA says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”.

Is the analogue cited by HHS the same as MOTS-c?

No. An analogue is a different molecule, and the trial HHS cites cannot establish the safety profile of MOTS-c itself.

Does a certificate of analysis tell me about side effects?

No. A certificate of analysis records tests for a batch. It cannot establish which reactions occur in people or how common they are.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page